Non-Human Primate (NHP) DMPK & PK/PD Evaluation Services

Are you currently facing challenges in translating preclinical data to human trials, struggling with long drug development cycles, or grappling with the complexities of PK/PD relationships for novel biologics? Our NHP DMPK & PK/PD Evaluation services help you accelerate drug development and obtain predictive, high-quality data through our advanced in vivo and in vitro platforms, offering unparalleled insights into drug efficacy and safety.

Introduction of Non-Human Primate DMPK & PK/PD Evaluation

What Our Service Is

Our services are designed to provide a comprehensive understanding of a drug's journey within a living system. In vivo PK (Pharmacokinetics) studies measure drug absorption, distribution, metabolism, and excretion (ADME) in a living organism. In vitro DMPK (Drug Metabolism and Pharmacokinetics) assays complement this by providing initial data on drug stability and metabolism in a controlled laboratory setting. Together, these services are critical for:

• Predicting Human Dose: Using NHP data to accurately predict the first-in-human dose and design safe and effective early-stage clinical trials.
• Evaluating Biologic Efficacy: Assessing the concentration-effect relationship for complex biologics like monoclonal antibodies (mAbs).
• Formulation Optimization: Guiding the selection of the most suitable drug formulation and route of administration for optimal therapeutic outcomes.

Why Choose Us?

The transition from preclinical studies to clinical trials is a major hurdle in drug development. Inconsistent data, poor translational models, and a lack of predictive power can lead to costly trial failures. Creative Biolabs addresses these pain points by providing highly translational NHP models, which share close genetic and immunological similarities to humans. Our services deliver predictive data that directly informs your clinical strategy, reducing risk and accelerating your path to market.

Fig.1 Cross-NHPs species reactivity assessment via flow cytometry and whole blood profiling.¹

Key Benefits of Our Service

Creative Biolabs' NHP DMPK & PK/PD Evaluation services offer key advantages that set us apart. We provide a unique platform that leverages our extensive resources and deep scientific expertise to deliver high-quality, actionable data.

• Unmatched NHP Resources: We have access to an extensive population of readily available non-human primates, including Cynomolgus, Rhesus, Marmoset, and African Green Monkey, enabling us to initiate and complete your studies with exceptional response speed, minimizing delays in your drug development timeline.
• Tailored Customization: Our experienced team designs and implements bespoke study protocols to meet the specific requirements of your unique therapeutic agent, whether it's an inhaled drug, a nucleic acid therapy, or a complex ADC.
• In-Depth Reporting: Our comprehensive final reports go beyond raw data. We provide detailed analysis and expert interpretation of the results, including PK modeling and PK/PD relationships, to help you make informed decisions.
• Proven Success: Our capabilities have been instrumental in supporting the development of numerous novel compounds. Published data and success stories demonstrate our ability to provide the critical data necessary for regulatory submissions and clinical progression.

Discover the Benefits of Creative Biolabs – Request Your Quote Now!

How Creative Biolabs' Non-Human Primate DMPK & PK/PD Evaluation Can Assist Your Project?

Creative Biolabs' NHP DMPK & PK/PD Evaluation services are designed to provide a clear and direct path to actionable insights for your project. We deliver a systematic, end-to-end solution that takes you from initial study design to final data interpretation, providing the confidence you need to move your candidate drug forward.

Key Deliverables

Clients receive a complete package of study documentation to support their regulatory submissions and internal decision-making. Our deliverables include:

• A detailed laboratory report with a clear executive summary.
• All raw data files in a client-friendly format.
• PK/PD modeling annotations and graphical representations.
• A certificate of analysis for the test article.
• A summary of all procedures, including animal care records.

Capabilities & Partnerships

Service-Specific Data

• Annual Sample Size: Over 50,000 samples analyzed per year.
• Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
• Study Pass Rate: 99%+ success rate in meeting study endpoints.

Our Valued Partners

Frequently Asked Questions

Contact Us

Creative Biolabs' Non-Human Primate DMPK & PK/PD Evaluation services provide a critical advantage in preclinical drug development. Our expertise, advanced platforms, and commitment to quality and ethical standards deliver the predictive data you need to confidently move your therapeutic candidates toward the clinic. Partner with us to streamline your R&D process and accelerate your path to market. To learn more about how our services can benefit your specific project, please reach out to our team of experts. We are ready to discuss your needs in detail and provide a tailored solution.